NASDAQ:GLYC GlycoMimetics (GLYC) Stock Price, News & Analysis $0.27 -0.03 (-10.04%) (As of 07/2/2024 ET) Add Compare Share Share Today's Range$0.27▼$0.3050-Day Range$0.24▼$1.8652-Week Range$0.24▼$3.53Volume1.15 million shsAverage Volume2.37 million shsMarket Capitalization$17.33 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get GlycoMimetics alerts: Email Address GlycoMimetics MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside3,620.2% Upside$10.00 Price TargetShort InterestHealthy2.73% of Shares Sold ShortDividend StrengthN/ASustainability-0.55Upright™ Environmental ScoreNews Sentiment0.95Based on 3 Articles This WeekInsider TradingAcquiring Shares$47,500 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.62) to ($0.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.65 out of 5 starsMedical Sector59th out of 914 stocksPharmaceutical Preparations Industry18th out of 433 stocks 3.0 Analyst's Opinion Consensus RatingGlycoMimetics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageGlycoMimetics has only been the subject of 2 research reports in the past 90 days.Read more about GlycoMimetics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.73% of the outstanding shares of GlycoMimetics have been sold short.Short Interest Ratio / Days to CoverGlycoMimetics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GlycoMimetics has recently decreased by 15.79%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldGlycoMimetics does not currently pay a dividend.Dividend GrowthGlycoMimetics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGlycoMimetics has received a 73.56% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for GlycoMimetics is -0.55. Previous Next 2.2 News and Social Media Coverage News SentimentGlycoMimetics has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for GlycoMimetics this week, compared to 1 article on an average week.Search InterestOnly 5 people have searched for GLYC on MarketBeat in the last 30 days. This is a decrease of -69% compared to the previous 30 days.MarketBeat FollowsOnly 9 people have added GlycoMimetics to their MarketBeat watchlist in the last 30 days. This is a decrease of -10% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GlycoMimetics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $47,500.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 8.70% of the stock of GlycoMimetics is held by insiders.Percentage Held by Institutions75.19% of the stock of GlycoMimetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about GlycoMimetics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for GlycoMimetics are expected to grow in the coming year, from ($0.62) to ($0.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GlycoMimetics is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GlycoMimetics is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGlycoMimetics has a P/B Ratio of 0.45. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about GlycoMimetics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsMajor Pharma Deals Propel This Undervalued AI StockYou need to check out this game-changing biotech stock. Their physics-based software can model how molecules behave and identify ideal drug candidates in record time. Big Pharma is taking notice.Reveal the AI Company Disrupting Drug Discovery Here >>> About GlycoMimetics Stock (NASDAQ:GLYC)GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.Read More GLYC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GLYC Stock News HeadlinesJune 25, 2024 | insidertrades.comGlycoMimetics, Inc. (NASDAQ:GLYC) Insider Buys $47,500.00 in StockJuly 2 at 3:42 AM | americanbankingnews.comGlycoMimetics (NASDAQ:GLYC) Coverage Initiated at StockNews.comJuly 2, 2024 | Digital Mavericks Media (Ad)1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income every month.June 25, 2024 | americanbankingnews.comGlycoMimetics, Inc. (NASDAQ:GLYC) Insider Edwin Rock Buys 190,000 SharesJune 24, 2024 | americanbankingnews.comGlycoMimetics (NASDAQ:GLYC) Now Covered by Analysts at StockNews.comJune 4, 2024 | businesswire.comGlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)May 29, 2024 | businesswire.comGlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024May 28, 2024 | finance.yahoo.comPipeline Moves: Phase III AML trial fails to meet primary endpointJuly 2, 2024 | Digital Mavericks Media (Ad)1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income every month.May 10, 2024 | msn.comGlycoMimetics GAAP EPS of -$0.17 in-lineMay 9, 2024 | msn.comGlycoMimetics Q1 2024 Earnings PreviewMay 8, 2024 | markets.businessinsider.comSell Rating on Lyra Therapeutics Amid Phase 3 Study Failure and Funding ConcernsMay 7, 2024 | msn.comHC Wainwright & Co. Downgrades GlycoMimetics (GLYC)May 6, 2024 | msn.comGlycoMimetics' Uproleselan Flunks In Late Stage Leukemia Study, Shares SinkMay 6, 2024 | markets.businessinsider.comWhy Is GlycoMimetics Stock Falling In Pre-market?May 6, 2024 | marketwatch.comGlycoMimetics Shares Drop After Leukemia Treatment Trial Fails to Meet Primary EndpointMay 6, 2024 | businesswire.comGlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)April 28, 2024 | finance.yahoo.comWe're Keeping An Eye On GlycoMimetics' (NASDAQ:GLYC) Cash Burn RateApril 27, 2024 | finance.yahoo.comGlycoMimetics, Inc. (GLYC)April 25, 2024 | businesswire.comGlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024April 15, 2024 | money.usnews.comGlycoMimetics IncApril 1, 2024 | finance.yahoo.comLoss-Making GlycoMimetics, Inc. (NASDAQ:GLYC) Expected To Breakeven In The Medium-TermMarch 28, 2024 | finance.yahoo.comGlycoMimetics, Inc. (NASDAQ:GLYC) Q4 2023 Earnings Call TranscriptMarch 28, 2024 | markets.businessinsider.comPositive Outlook for GlycoMimetics: Buy Rating Affirmed Amid Anticipated Pivotal Trial Results and Strategic Growth InitiativesMarch 28, 2024 | finance.yahoo.comQ4 2023 GlycoMimetics Inc Earnings CallMarch 27, 2024 | markets.businessinsider.comBuy Rating on GlycoMimetics Backed by Strong Financials and Promising Phase 3 Trial of UproleselanMarch 27, 2024 | markets.businessinsider.comBuy Recommendation for GlycoMimetics Based on Promising Upro Drug Prospects and Strong PipelineSee More Headlines Receive GLYC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GlycoMimetics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/02/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GLYC CUSIPN/A CIK1253689 Webwww.glycomimetics.com Phone(240) 243-1201Fax301-738-2137Employees35Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$12.00 Low Stock Price Target$8.00 Potential Upside/Downside+3,497.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,900,000.00 Net MarginsN/A Pretax Margin-372,770.03% Return on Equity-88.40% Return on Assets-76.65% Debt Debt-to-Equity RatioN/A Current Ratio6.28 Quick Ratio6.28 Sales & Book Value Annual Sales$10,000.00 Price / Sales1,791.99 Cash FlowN/A Price / Cash FlowN/A Book Value$0.60 per share Price / Book0.46Miscellaneous Outstanding Shares64,460,000Free Float58,856,000Market Cap$17.92 million OptionableOptionable Beta2.19 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Harout Semerjian (Age 54)CEO, President & Director Comp: $1.13MMs. Rachel K. King (Age 65)Co-Founder & Director Comp: $40kMr. Brian M. Hahn (Age 50)Senior VP & CFO Comp: $822.12kDr. Edwin Rock M.D. (Age 63)Ph.D., Senior VP & Chief Medical Officer Comp: $677.4kMs. Stephanie R. Irish CPA (Age 53)Vice President of Accounting Mr. Christian B. Dinneen-LongGeneral Counsel & Company SecretaryMr. Bruce Johnson (Age 56)Senior VP & Chief Commercial Officer Mr. Chinmaya Rath (Age 47)Senior VP & Chief Business Officer Mr. Shantha Tyavanagimatt Ph.D.Senior Vice President of Technical OperationsMore ExecutivesKey CompetitorsAnixa BiosciencesNASDAQ:ANIXMediciNovaNASDAQ:MNOVEupraxia PharmaceuticalsNASDAQ:EPRXMilestone PharmaceuticalsNASDAQ:MISTSpero TherapeuticsNASDAQ:SPROView All CompetitorsInsiders & InstitutionsEdwin RockBought 190,000 shares on 6/20/2024Total: $47,500.00 ($0.25/share)Ikarian Capital LLCBought 172,800 shares on 5/17/2024Ownership: 0.000%NEA Management Company LLCSold 929,401 shares on 5/15/2024Ownership: 5.949%Affinity Asset Advisors LLCBought 142,300 shares on 5/15/2024Ownership: 0.000%Vanguard Group Inc.Bought 340,112 shares on 5/10/2024Ownership: 4.285%View All Insider TransactionsView All Institutional Transactions GLYC Stock Analysis - Frequently Asked Questions Should I buy or sell GlycoMimetics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" GLYC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GLYC, but not buy additional shares or sell existing shares. View GLYC analyst ratings or view top-rated stocks. What is GlycoMimetics' stock price target for 2024? 2 Wall Street analysts have issued 12-month price targets for GlycoMimetics' shares. Their GLYC share price targets range from $8.00 to $12.00. On average, they predict the company's share price to reach $10.00 in the next year. This suggests a possible upside of 3,620.2% from the stock's current price. View analysts price targets for GLYC or view top-rated stocks among Wall Street analysts. How have GLYC shares performed in 2024? GlycoMimetics' stock was trading at $2.36 at the beginning of the year. Since then, GLYC stock has decreased by 88.6% and is now trading at $0.2688. View the best growth stocks for 2024 here. Are investors shorting GlycoMimetics? GlycoMimetics saw a decline in short interest in the month of June. As of June 15th, there was short interest totaling 1,760,000 shares, a decline of 15.8% from the May 31st total of 2,090,000 shares. Based on an average daily volume of 4,150,000 shares, the short-interest ratio is currently 0.4 days. View GlycoMimetics' Short Interest. When is GlycoMimetics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our GLYC earnings forecast. How were GlycoMimetics' earnings last quarter? GlycoMimetics, Inc. (NASDAQ:GLYC) released its quarterly earnings results on Thursday, May, 9th. The biotechnology company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.16) by $0.01. What other stocks do shareholders of GlycoMimetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other GlycoMimetics investors own include Exelixis (EXEL), TG Therapeutics (TGTX), Viking Therapeutics (VKTX), Cidara Therapeutics (cdtx), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), Spectrum Pharmaceuticals (SPPI), Coherus BioSciences (CHRS), Verastem (VSTM) and Aldeyra Therapeutics (ALDX). How do I buy shares of GlycoMimetics? Shares of GLYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GLYC) was last updated on 7/2/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredRe: We’re giving you all this for less than a pair of socksThe Only Trading Tool You'll Need This Year Forget juggling multiple subscriptions and confusing indicator...StockEarnings | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | Sponsored270x more lucrative than NVIDIA???If you've missed out on NVIDIA's recent 1,600% run... Don't worry. Because there's one AI stock that cou...Behind the Markets | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlycoMimetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GlycoMimetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.